Summary

The AI in life science market is projected to reach USD 69.34 billion by 2031, up from USD 21.58 billion in 2026, at a high CAGR of 26.3% over the forecast period.

https://mnmimg.marketsandmarkets.com/Images/ai-in-life-science-market-img-overview.webp

The growth rate is further fueled by the growing trend toward data-oriented and agentic AI architectures that help life science companies advance from conventional analytics to self-acting systems. These innovations particularly impact clinical trial optimization, real-world evidence collection, and post-market monitoring, as fragmented and vast data sets have limited the efficiency of these applications. In addition, the adoption of cloud-based services with AI technology allows life science companies to consolidate diverse data sources, ranging from medical and genomics data to patient-specific information, to facilitate predictive modeling and fast-track the drug development process. The emergence of AI agents that automate sophisticated tasks, such as literature search, hypothesis formulation, and patient segmentation, also contributes to increased operational efficiency and accelerated innovation cycles. For example, Oracle Corporation (US) released the Oracle Life Sciences AI Data Platform in January 2026, which combines more than 129 million de-identified medical records with generative AI and agentic intelligence solutions to speed up research and clinical trials. In addition, IQVIA Holdings Inc. (US) introduced AI agents in June 2025 to optimize workflows in clinical and commercial operations, including target identification and clinical data analytics.
Based on region, the AI in life science market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America is the dominant region in the global AI in life science market owing to the presence of sophisticated research networks, high levels of digitalization, and considerable investment in innovations in biotechnology and pharma. The region leverages its strengths in terms of synergies between universities, hospitals, and tech companies, helping to implement AI-driven advancements more quickly. Moreover, a positive regulatory environment and rapid adoption of sophisticated analytics in drug discovery and clinical trials have helped to consolidate the region's position as a leader in this market. Europe is the second-largest market in the segment due to the growing interest of governments and companies in Al technology and AI products compliant with data privacy requirements.
Based on offerings, the AI in life science market is divided into end-to-end solutions, niche/point solutions, AI technology, and services. In 2025, end-to-end solutions had the largest market share due to increasing demand for integrated platforms that support data ingestion, model building, validation, and deployment across the entire life sciences value chain. These solutions make the life sciences workflow more efficient and cohesive, from target identification to clinical and commercial levels. Companies in the industry now tend to prefer full-stack AI platforms over stand-alone software for their ability to scale, comply with regulations, and enable collaboration across functions. This shift reflects a broader market trend moving from experimental AI applications toward enterprise-level implementation that requires consistent, repeatable, and auditable processes for research and development and clinical trials. For example, in October 2025, the Italian organization expert.ai launched AI-powered solutions to optimize clinical trial design and regulatory and research workflows. Additionally, in June 2025, ArisGlobal (US) implemented its LifeSphere NavaX AI platform at a leading pharmaceutical company globally, enabling automated analysis of roughly 350,000 safety cases annually.
Based on application, the AI in life science market is divided into clinical applications and non-clinical applications. The clinical applications segment is expected to see the fastest growth in this market. This is attributed to the rise in the use of AI to improve patient experiences, conduct clinical trials more effectively, and adopt precision medicine through real-time data analysis. AI-powered software is helping to improve patient enrollment, trial management, and protocol optimization, thereby reducing trial periods and improving success rates. In addition, the transition toward patient-focused, decentralized clinical trials is driving the adoption of AI-powered software. This trend was reflected in the following development. By March 2026, IQVIA had deployed over 150 AI agents, which were used by 19 of the top 20 pharmaceutical firms. In June 2025, IQVIA Holdings Inc. (US) released AI agents to streamline clinical operations.

ページTOPに戻る

Table of Contents

1 INTRODUCTION 36
1.1 STUDY OBJECTIVES 36
1.2 MARKET DEFINITION 36
1.3 STUDY SCOPE 37
1.3.1 MARKET SEGMENTATION AND REGIONAL SCOPE 37
1.3.2 INCLUSIONS AND EXCLUSIONS 38
1.3.3 YEARS CONSIDERED 39
1.4 CURRENCY CONSIDERED 39
1.5 STAKEHOLDERS 40
2 EXECUTIVE SUMMARY 41
2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS 41
2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND STRATEGIC DEVELOPMENTS 42
2.3 DISRUPTIVE TRENDS SHAPING THE MARKET 43
2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS 44
2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST 45
3 PREMIUM INSIGHTS 46
3.1 AI IN LIFE SCIENCE MARKET OVERVIEW 46
3.2 AI IN LIFE SCIENCE MARKET, BY APPLICATION & REGION 47
3.3 AI IN LIFE SCIENCE MARKET: REGIONAL SNAPSHOT 47
4 MARKET OVERVIEW 48
4.1 INTRODUCTION 48
4.2 MARKET DYNAMICS 49
4.2.1 DRIVERS 49
4.2.1.1 Surging demand for accelerated drug discovery and R&D pipeline optimization 49
4.2.1.2 Growing cross-industry partnerships 50
4.2.1.3 Expanding applications of AI in clinical trial design, patient recruitment, and operational efficiency 51
4.2.1.4 Growing availability of large-scale biomedical datasets and advances in computing infrastructure 51
4.2.1.5 Supportive government policies, funding initiatives, and regulatory frameworks 52
4.2.2 RESTRAINTS 52
4.2.2.1 Data privacy and cybersecurity concerns 52
4.2.2.2 Algorithmic bias and clinician trust deficits 52
4.2.2.3 High implementation costs, technical complexity, and integration challenges with legacy IT systems 53
4.2.3 OPPORTUNITIES 53
4.2.3.1 Generative AI and foundation models for de novo drug design 53
4.2.3.2 Rising focus on rare disease treatments 54
4.2.3.3 Growing demand for precision and personalized medicine 54
4.2.3.4 AI integration in academic research institutes and government-backed biomedical innovation programs 55
4.2.4 CHALLENGES 55
4.2.4.1 Low data fragmentation, interoperability deficits 55
4.2.4.2 Talent scarcity and organizational readiness 56
4.3 UNMET NEEDS AND WHITE SPACES 56
4.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES 56
4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 57
5 INDUSTRY TRENDS 58
5.1 PORTER’S FIVE FORCES ANALYSIS 58
5.1.1 BARGAINING POWER OF SUPPLIERS 59
5.1.2 BARGAINING POWER OF BUYERS 59
5.1.3 THREAT OF SUBSTITUTES 59
5.1.4 THREAT OF NEW ENTRANTS 59
5.1.5 INTENSITY OF COMPETITIVE RIVALRY 59
5.2 MACROECONOMIC INDICATORS 60
5.2.1 INTRODUCTION 60
5.2.2 GDP TRENDS AND FORECAST 60
5.2.3 TRENDS IN GLOBAL HEALTHCARE IT INDUSTRY 60
5.3 VALUE CHAIN ANALYSIS 60
5.4 ECOSYSTEM ANALYSIS 62
5.5 PRICING ANALYSIS 64
5.5.1 INDICATIVE PRICE FOR AI IN LIFE SCIENCE MARKET (2025) 64
5.5.2 INDICATIVE PRICE FOR AI IN LIFE SCIENCE MARKET, BY REGION (2025) 64
5.6 KEY CONFERENCES AND EVENTS, 2026?2027 65
5.7 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 66
5.8 INVESTMENT AND FUNDING SCENARIO 67
5.9 CASE STUDY ANALYSIS 67
5.10 IMPACT OF 2025 US TARIFF ? AI IN LIFE SCIENCE MARKET 69
5.10.1 INTRODUCTION 69
5.10.2 KEY TARIFF RATES 70
5.10.3 PRICE IMPACT ANALYSIS 71
5.10.4 IMPACT ON COUNTRY/REGION 71
5.10.4.1 US 71
5.10.4.2 Europe 71
5.10.4.3 Asia Pacific 71
?
5.10.5 IMPACT ON END USERS 72
5.10.5.1 CRO & CDMO 72
5.10.5.2 Pharmaceutical & biotechnology companies 72
5.10.5.3 Research centers & academic institutes 72
5.10.5.4 Diagnostic companies 72
6 REGULATORY LANDSCAPE 73
6.1 REGIONAL REGULATIONS AND COMPLIANCE 73
6.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 73
6.1.2 NORTH AMERICA 76
6.1.3 EUROPE 77
6.1.4 ASIA PACIFIC 78
6.1.5 MIDDLE EAST & AFRICA 79
6.1.6 LATIN AMERICA 79
6.1.7 INDUSTRY STANDARDS 80
7 STRATEGIC DISRUPTION THROUGH TECHNOLOGY, PATENTS, DIGITAL,
AND AI ADOPTION 81
7.1 KEY EMERGING TECHNOLOGIES 81
7.1.1 GRAPH NEURAL NETWORKS 81
7.1.2 COMPUTER VISION 81
7.1.3 PREDICTIVE ANALYTICS 81
7.2 COMPLEMENTARY TECHNOLOGIES 81
7.2.1 NEXT-GENERATION SEQUENCING 82
7.2.2 REAL-WORLD EVIDENCE/REAL-WORLD DATA 82
7.2.3 PERSONALIZATION ENGINES 82
7.3 ADJACENT TECHNOLOGIES 82
7.3.1 CLOUD COMPUTING 82
7.3.2 BLOCKCHAIN 83
7.3.3 BIG DATA & ADVANCED ANALYTICS 83
7.4 TECHNOLOGY/PRODUCT ROADMAP 83
7.5 PATENT ANALYSIS 84
7.5.1 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS 84
7.6 FUTURE APPLICATIONS 86
7.6.1 AI-DRIVEN DRUG DISCOVERY 86
7.6.2 GENOMIC ANALYSIS 87
7.6.3 PRECISION MEDICINE 87
7.6.4 VIRTUAL DRUG SCREENING 87
?
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 88
8.1 INTRODUCTION 88
8.2 DECISION-MAKING PROCESS 88
8.3 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA 88
8.3.1 KEY STAKEHOLDERS IN BUYING PROCESS 88
8.3.2 BUYING CRITERIA 89
8.4 ADOPTION BARRIERS & INTERNAL CHALLENGES 90
8.5 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES 91
8.5.1 UNMET NEEDS 91
8.5.2 END USER EXPECTATIONS 92
8.6 MARKET PROFITABILITY 93
9 AI IN LIFE SCIENCE MARKET, BY TOOL 94
9.1 INTRODUCTION 95
9.2 MACHINE LEARNING 95
9.2.1 DEEP LEARNING 97
9.2.1.1 Convolutional neural networks 98
9.2.1.1.1 High-sensitivity medical imaging AI across oncology and radiology pathways ? key driver 98
9.2.1.2 Recurrent neural networks 99
9.2.1.2.1 Sequential biological data processing drives adoption in clinical and genomic applications 99
9.2.1.3 Generative adversarial networks 100
9.2.1.3.1 Synthetic data generation to overcome life science data scarcity barriers boosts adoption 100
9.2.1.4 Graph neural networks 101
9.2.1.4.1 Graph AI architectures modeling molecular interactions to advance target and pathway discovery 101
9.2.1.5 Others 102
9.2.1.5.1 Transformer and diffusion architectures expanding deep learning frontiers in life sciences 102
9.2.2 SUPERVISED LEARNING 103
9.2.2.1 Segment driven by accurate prediction of compound potency and selectivity across diverse chemical series 103
9.2.3 REINFORCEMENT LEARNING 104
9.2.3.1 Optimized drug dosing, trial design, and autonomous laboratory systems to drive segment 104
9.2.4 UNSUPERVISED LEARNING 105
9.2.4.1 Unsupervised AI revealing hidden biological patterns within high-dimensional omics datasets 105
9.2.5 OTHER MACHINE LEARNING TECHNOLOGIES 106
9.2.5.1 Semi-supervised and federated learning overcome data scarcity and privacy constraints 106
?
9.3 NATURAL LANGUAGE PROCESSING 107
9.3.1 BIOMEDICAL LLMS AND CLINICAL NLP AUTOMATING KNOWLEDGE EXTRACTION FROM UNSTRUCTURED HEALTH DATA 107
9.4 CONTEXT-AWARE PROCESSING AND COMPUTING 108
9.4.1 SEGMENT DRIVEN BY DYNAMIC, PATIENT-SPECIFIC INSIGHTS ACROSS CLINICAL WORKFLOWS 108
9.5 COMPUTER VISION 109
9.5.1 TRANSFORMATION OF PATHOLOGY, DERMATOLOGY, AND DRUG MANUFACTURING INSPECTION PROCESSES ? KEY DRIVERS 109
9.6 IMAGE ANALYSIS 110
9.6.1 ACCELERATED DIGITAL PATHOLOGY, LAB IMAGING, AND DOCUMENT PROCESSING TO BOOST ADOPTION 110
9.7 OTHER TOOLS 111
10 AI IN LIFE SCIENCE MARKET, BY APPLICATION 113
10.1 INTRODUCTION 114
10.2 CLINICAL APPLICATIONS 114
10.2.1 REDUCED DEVELOPMENT TIMELINES AND IMPROVED CLINICAL SUCCESS TO DRIVE SEGMENT 114
10.2.2 DRUG DISCOVERY 116
10.2.2.1 AI-driven target identification transforming biopharma R&D productivity and success rates 116
10.2.3 MEDICAL IMAGING & DIAGNOSTICS 117
10.2.3.1 Accelerating FDA clearances and radiology digitization drives clinical AI imaging adoption 117
10.2.4 CLINICAL TRIALS 118
10.2.4.1 AI-powered trial optimization and decentralized models accelerating patient-centric research 118
10.2.5 PRECISION MEDICINE 119
10.2.5.1 Multi-Omics AI integration enabling individualized therapy selection at population scale 119
10.2.6 OTHER CLINICAL APPLICATIONS 120
10.2.6.1 AI-augmented clinical decision support expanding into pharmacovigilance and rare disease 120
10.3 NON-CLINICAL APPLICATIONS 121
10.3.1 R&D SUPPORT 122
10.3.1.1 AI-enabled literature mining and lab automation multiplying R&D throughput significantly 122
10.3.2 DATA ANALYTICS & REPORTING 123
10.3.2.1 Real-world evidence and AI analytics transforming strategic decision-making across organizations 123
10.3.3 MANUFACTURING & QUALITY ASSURANCE 124
10.3.3.1 Predictive quality AI and continuous manufacturing reduce batch failures and compliance risk 124
?
10.3.4 REGULATORY AFFAIRS 125
10.3.4.1 FDA and EMA AI guidance catalyzing regulatory submission automation and pharmacovigilance efficiency 125
11 AI IN LIFE SCIENCE MARKET, BY COMPONENT 126
11.1 INTRODUCTION 127
11.2 SOFTWARE 127
11.2.1 AI SOFTWARE PLATFORMS BECOMING CORE INFRASTRUCTURE FOR LIFE SCIENCE DIGITAL TRANSFORMATION 127
11.3 SERVICE 128
11.3.1 SPECIALIZED AI SERVICES BRIDGING VALIDATION AND COMPLIANCE GAPS ACROSS LIFE SCIENCE ENTERPRISES 128
12 AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT 130
12.1 INTRODUCTION 131
12.2 CLOUD-BASED SOLUTIONS 131
12.2.1 HYPERSCALE CLOUD INFRASTRUCTURE ACCELERATES LIFE SCIENCE AI SCALABILITY AND COLLABORATIVE RESEARCH 131
12.3 ON-PREMISE SOLUTIONS 132
12.3.1 DATA SOVEREIGNTY AND GXP COMPLIANCE SUSTAIN ON-PREMISE AI DEPLOYMENT ACROSS REGULATED ENVIRONMENTS 132
12.4 HYBRID SOLUTIONS 133
12.4.1 HYBRID ARCHITECTURES BALANCE REGULATORY COMPLIANCE, DATA SECURITY, AND AI SCALABILITY DEMANDS 133
13 AI IN LIFE SCIENCE MARKET, BY END USER 135
13.1 INTRODUCTION 136
13.2 CRO & CDMO 136
13.2.1 AI-POWERED CROS & CDMOS COMPETE ON SPEED, QUALITY, AND DATA INTELLIGENCE DIFFERENTIATION 136
13.3 PHARMACEUTICAL COMPANIES 137
13.3.1 AI EMBEDDED ACROSS DISCOVERY, TRIALS, AND COMMERCIAL OPERATIONS BROADLY BY PHARMA LEADERS 137
13.4 BIOTECHNOLOGY COMPANIES 138
13.4.1 AI-NATIVE BIOTECH MODELS COMPRESSING DRUG DISCOVERY TIMELINES FROM YEARS TO MONTHS 138
13.5 DIAGNOSTIC COMPANIES 139
13.5.1 AI-AUGMENTED DIAGNOSTICS ELEVATE SENSITIVITY AND THROUGHPUT ACROSS MOLECULAR AND IMAGING PLATFORMS 139
13.6 ACADEMIC & GOVERNMENT LABORATORIES 140
13.6.1 PUBLIC AI RESEARCH PROGRAMS AND OPEN SCIENCE INITIATIVES BUILD FOUNDATIONAL LIFE SCIENCE INFRASTRUCTURE 140
13.7 OTHER END USERS 141
?
14 AI IN LIFE SCIENCE MARKET, BY OFFERING 143
14.1 INTRODUCTION 144
14.2 END-TO-END SOLUTION 144
14.2.1 INTEGRATED AI PLATFORMS COMPRESSING DRUG DEVELOPMENT TIMELINES ACROSS ENTIRE VALUE CHAINS 144
14.3 NICHE/POINT SOLUTIONS 145
14.3.1 DISEASE-SPECIFIC AI TOOLS DELIVER MEASURABLE OUTCOMES IN TARGETED RESEARCH WORKFLOWS 145
14.4 AI TECHNOLOGY 146
14.4.1 FOUNDATION MODELS AND GENERATIVE AI REDEFINE CORE SCIENTIFIC DISCOVERY CAPABILITIES 146
14.5 SERVICES 147
14.5.1 PROFESSIONAL AI SERVICES ENABLE COMPLIANT DEPLOYMENT ACROSS REGULATED LIFE SCIENCE ENVIRONMENTS 147
15 AI IN LIFE SCIENCE MARKET, BY REGION 149
15.1 INTRODUCTION 150
15.2 NORTH AMERICA 151
15.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 152
15.2.2 US 157
15.2.2.1 Record FDA approvals and federal funding propel AI medical device commercialization 157
15.2.3 CANADA 163
15.2.3.1 Federal AI investment and sovereign compute strategy catalyze life sciences innovation 163
15.3 EUROPE 168
15.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 168
15.3.2 GERMANY 174
15.3.2.1 Prescription digital health app framework propels market 174
15.3.3 FRANCE 179
15.3.3.1 National AI-health data strategy and health data hub anchor data-driven life sciences 179
15.3.4 UK 185
15.3.4.1 NHS Ten-Year Plan positions AI as core infrastructure for national care transformation 185
15.3.5 ITALY 190
15.3.5.1 National recovery plan digitization funding opens new hospital AI adoption pathways 190
15.3.6 SPAIN 195
15.3.6.1 National AI strategy and SNS digitization align life sciences sector with EU AI ambitions 195
15.3.7 REST OF EUROPE 200
?
15.4 ASIA PACIFIC 206
15.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 206
15.4.2 CHINA 212
15.4.2.1 NMPA high-end device policy and AI standardization body streamline AI commercialization 212
15.4.3 JAPAN 217
15.4.3.1 PMDA adaptive AI framework and medical DX reforms accelerate SaMD commercialization 217
15.4.4 INDIA 222
15.4.4.1 IndiaAI mission and national health data infrastructure enable population-scale AI deployment 222
15.4.5 AUSTRALIA 228
15.4.5.1 My Health Record ecosystem and TGA SaMD pathways underpin AI-ready digital infrastructure 228
15.4.6 SOUTH KOREA 233
15.4.6.1 K-Medtech ecosystem and MFDS AI regulatory guidance propel smart hospital AI adoption 233
15.4.7 REST OF ASIA PACIFIC 239
15.5 LATIN AMERICA 245
15.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 245
15.5.2 BRAZIL 250
15.5.2.1 RNDS National Health Network provides digital backbone for AI healthcare integration 250
15.5.3 MEXICO 256
15.5.3.1 IMSS digital transformation and National AI Strategy drive AI integration into public healthcare 256
15.5.4 REST OF LATIN AMERICA 261
15.6 MIDDLE EAST & AFRICA 267
15.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 267
15.6.2 GCC 273
15.6.3 SAUDI ARABIA 278
15.6.3.1 Vision 2030 health sector transformation program drives AI-enabled care delivery at scale 278
15.6.4 UAE 284
15.6.4.1 Malaffi, NABIDH interoperability and Emirati Genome Programme establish AI-ready data foundation 284
15.6.5 REST OF GCC 289
15.6.5.1 Rising demand for telehealth & virtual care to propel market 289
15.6.6 SOUTH AFRICA 294
15.6.6.1 National health insurance framework and digital health programs catalyze AI market entry 294
15.6.7 REST OF MIDDLE EAST & AFRICA 299
?
16 COMPETITIVE LANDSCAPE 305
16.1 OVERVIEW 305
16.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 305
16.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN AI IN LIFE SCIENCE MARKET 306
16.3 REVENUE ANALYSIS 308
16.4 MARKET SHARE ANALYSIS, 2025 309
16.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 311
16.5.1 STARS 311
16.5.2 EMERGING LEADERS 311
16.5.3 PERVASIVE PLAYERS 311
16.5.4 PARTICIPANTS 312
16.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 313
16.5.5.1 Company footprint 313
16.5.5.2 Region footprint 314
16.5.5.3 Offering footprint 315
16.5.5.4 Application footprint 316
16.5.5.5 End user footprint 317
16.5.5.6 Tools footprint 318
16.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 319
16.6.1 PROGRESSIVE COMPANIES 319
16.6.2 RESPONSIVE COMPANIES 319
16.6.3 DYNAMIC COMPANIES 319
16.6.4 STARTING BLOCKS 319
16.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025 321
16.6.5.1 Detailed list of key startups/SMEs 321
16.6.5.2 Competitive benchmarking of startups/SMEs 322
16.7 VALUATION & FINANCIAL METRICS 323
16.7.1 FINANCIAL METRICS 323
16.7.2 COMPANY VALUATION 323
16.8 BRAND/SOFTWARE COMPARISON 324
16.9 COMPETITIVE SCENARIO 325
16.9.1 PRODUCT/SERVICE LAUNCHES & APPROVALS 325
16.9.2 DEALS 326
16.9.3 EXPANSIONS 327
?
17 COMPANY PROFILES 328
17.1 KEY PLAYERS 328
17.1.1 NVIDIA CORPORATION 328
17.1.1.1 Business overview 328
17.1.1.2 Products/Solutions offered 329
17.1.1.3 Recent developments 330
17.1.1.3.1 Product launches & enhancements 330
17.1.1.3.2 Deals 331
17.1.1.3.3 Other developments 334
17.1.1.4 MnM view 334
17.1.1.4.1 Key strengths 334
17.1.1.4.2 Strategic choices 334
17.1.1.4.3 Weaknesses and competitive threats 335
17.1.2 ILLUMINA, INC. 336
17.1.2.1 Business overview 336
17.1.2.2 Products/Solutions offered 337
17.1.2.3 Recent developments 338
17.1.2.3.1 Product launches & enhancements 338
17.1.2.3.2 Deals 340
17.1.2.4 MnM view 341
17.1.2.4.1 Key strengths 341
17.1.2.4.2 Strategic choices 341
17.1.2.4.3 Weaknesses and competitive threats 342
17.1.3 TEMPUS AI, INC. 343
17.1.3.1 Business overview 343
17.1.3.2 Products offered 344
17.1.3.3 Recent developments 345
17.1.3.3.1 Deals 345
17.1.3.3.2 Other developments 345
17.1.4 RECURSION 346
17.1.4.1 Business overview 346
17.1.4.2 Products/Solutions offered 347
17.1.4.3 Recent developments 348
17.1.4.3.1 Product launches & enhancements 348
17.1.4.3.2 Deals 348
17.1.4.3.3 Expansions 350
17.1.4.4 MnM view 350
17.1.4.4.1 Key strengths 350
17.1.4.4.2 Strategic choices 351
17.1.4.4.3 Weaknesses and competitive threats 351
?
17.1.5 DASSAULT SYST?MES SE 352
17.1.5.1 Business overview 352
17.1.5.2 Products offered 353
17.1.5.3 Recent developments 354
17.1.5.3.1 Product launches & enhancements 354
17.1.5.3.2 Deals 354
17.1.5.3.3 Other developments 355
17.1.6 SCHR?DINGER, INC. 356
17.1.6.1 Business overview 356
17.1.6.2 Products/Solutions offered 357
17.1.6.3 Recent developments 358
17.1.6.3.1 Deals 358
17.1.6.3.2 Other Developments 359
17.1.7 DATA4CURE, INC. 360
17.1.7.1 Business overview 360
17.1.7.2 Products offered 360
17.1.7.3 Recent developments 361
17.1.7.3.1 Product launches & enhancements 361
17.1.7.3.2 Other developments 361
17.1.8 MICROSOFT CORPORATION 362
17.1.8.1 Business overview 362
17.1.8.2 Products offered 363
17.1.8.3 Recent developments 364
17.1.8.3.1 Product launches & enhancements 364
17.1.8.3.2 Deals 365
17.1.8.3.3 Other developments 365
17.1.9 INSILICO MEDICINE 366
17.1.9.1 Business overview 366
17.1.9.2 Products/Services offered 366
17.1.9.3 Recent developments 367
17.1.9.3.1 Product launches & enhancements 367
17.1.9.3.2 Deals 368
17.1.9.3.3 Other developments 370
17.1.9.3.4 Expansions 370
17.1.10 EUROFINS DISCOVERY 371
17.1.10.1 Business overview 371
17.1.10.2 Products offered 371
17.1.10.3 Recent developments 372
17.1.10.3.1 Product launches & approvals 372
17.1.10.3.2 Deals 372
?
17.1.11 BENEVOLENTAI LIMITED 373
17.1.11.1 Business overview 373
17.1.11.2 Products offered 373
17.1.11.3 Recent developments 374
17.1.11.3.1 Deals 374
17.1.12 OWKIN 375
17.1.12.1 Business overview 375
17.1.12.2 Products offered 375
17.1.12.3 Recent developments 376
17.1.12.3.1 Product launches & approvals 376
17.1.12.3.2 Deals 377
17.1.12.3.3 Other developments 377
17.1.13 PATHAI 378
17.1.13.1 Business overview 378
17.1.13.2 Products offered 378
17.1.13.3 Recent developments 379
17.1.13.3.1 Product launches & approvals 379
17.1.13.3.2 Deals 379
17.1.14 AIDOC MEDICAL LTD. 380
17.1.14.1 Business overview 380
17.1.14.2 Products offered 380
17.1.14.3 Recent developments 381
17.1.14.3.1 Product launches & approvals 381
17.1.14.3.2 Other developments 382
17.1.15 QURE.AI 383
17.1.15.1 Business overview 383
17.1.15.2 Products offered 383
17.1.15.3 Recent developments 384
17.1.15.3.1 Product launches & approvals 384
17.1.16 DEEP GENOMICS 385
17.1.16.1 Business overview 385
17.1.16.2 Products offered 385
17.1.16.3 Recent developments 386
17.1.16.3.1 Expansions 386
17.1.17 SOPHIA GENETICS SA 387
17.1.17.1 Business overview 387
17.1.17.2 Products offered 388
17.1.17.3 Recent developments 389
17.1.17.3.1 Product launches & enhancements 389
17.1.17.3.2 Deals 389
?
17.1.18 UNLEARN.AI 390
17.1.18.1 Business overview 390
17.1.18.2 Products offered 390
17.1.18.3 Recent developments 391
17.1.18.3.1 Deals 391
17.1.19 VERGE GENOMICS 392
17.1.19.1 Business overview 392
17.1.19.2 Products offered 392
17.1.19.3 Recent developments 393
17.1.19.3.1 Deals 393
17.2 OTHER PLAYERS 394
17.2.1 SYNTHIO LABS LTD 394
17.2.2 BIOPTIMUS 394
17.2.3 KARYON BIO 395
17.2.4 COUNTERFORCE HEALTH 395
17.2.5 PROMISE BIO 396
18 RESEARCH METHODOLOGY 397
18.1 RESEARCH APPROACH 397
18.1.1 SECONDARY RESEARCH 398
18.1.1.1 Key data from secondary sources 399
18.1.2 PRIMARY RESEARCH 399
18.1.2.1 Primary sources 400
18.1.2.2 Key data from primary sources 401
18.1.2.3 Breakdown of primary interviews 401
18.1.2.4 Insights from primary experts 402
18.2 RESEARCH METHODOLOGY DESIGN 402
18.3 MARKET SIZE ESTIMATION 404
18.4 DATA TRIANGULATION 409
18.5 RESEARCH ASSUMPTIONS 410
18.6 RESEARCH LIMITATIONS 410
18.6.1 METHODOLOGY-RELATED 410
18.6.2 SCOPE-RELATED 411
18.7 RISK ASSESSMENT 411
19 APPENDIX 412
19.1 DISCUSSION GUIDE 412
19.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 418
19.3 CUSTOMIZATION OPTIONS 420
19.4 RELATED REPORTS: 420
19.5 AUTHOR DETAILS 421

ページTOPに戻る

List of Tables/Graphs

TABLE 1 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD 40
TABLE 2 AI IN LIFE SCIENCE MARKET: PORTER’S FIVE FORCES ANALYSIS 59
TABLE 3 AI IN LIFE SCIENCE MARKET: ROLE IN ECOSYSTEM 63
TABLE 4 CASE 1: GENERATIVE AI ACCELERATES DRUG DISCOVERY, CLINICAL RESEARCH, AND OPERATIONAL EFFICIENCY IN LIFE SCIENCES 67
TABLE 5 CASE 2: JOHNSON & JOHNSON EXPANDS AI INTEGRATION ACROSS DRUG DISCOVERY, SURGICAL INNOVATION, AND HEALTHCARE OPERATIONS 68
TABLE 6 CASE 3: AI-DRIVEN DRUG DISCOVERY AND CLINICAL OPTIMIZATION ACCELERATE INNOVATION IN LIFE SCIENCES 69
TABLE 7 US ADJUSTED RECIPROCAL TARIFF RATES 70
TABLE 8 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 73
TABLE 9 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 74
TABLE 10 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 75
TABLE 11 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 76
TABLE 12 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 76
TABLE 13 JURISDICTION ANALYSIS OF TOP APPLICANT COUNTRIES FOR AI IN LIFE SCIENCE MARKET 84
TABLE 14 AI IN LIFE SCIENCE MARKET: KEY PATENTS/PATENT APPLICATIONS 86
TABLE 15 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF
TOP THREE END USERS (%) 89
TABLE 16 KEY BUYING CRITERIA FOR TOP THREE END USERS 90
TABLE 17 UNMET NEEDS IN AI IN LIFE SCIENCE MARKET 91
TABLE 18 END USER EXPECTATIONS IN AI IN LIFE SCIENCE MARKET 92
TABLE 19 AI IN LIFE SCIENCE MARKET, BY TOOL, 2024?2031 (USD MILLION) 95
TABLE 20 AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE,
2024?2031 (USD MILLION) 96
TABLE 21 AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY REGION,
2024?2031 (USD MILLION) 96
TABLE 22 AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE,
2024?2031 (USD MILLION) 97
TABLE 23 AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY REGION,
2024?2031 (USD MILLION) 98
TABLE 24 AI IN LIFE SCIENCE MARKET FOR CONVOLUTIONAL NEURAL NETWORKS,
BY REGION, 2024?2031 (USD MILLION) 99
TABLE 25 AI IN LIFE SCIENCE MARKET FOR RECURRENT NEURAL NETWORKS, BY REGION, 2024?2031 (USD MILLION) 100
TABLE 26 AI IN LIFE SCIENCE MARKET FOR GENERATIVE ADVERSARIAL NETWORKS,
BY REGION, 2024?2031 (USD MILLION) 101
TABLE 27 AI IN LIFE SCIENCE MARKET FOR GRAPH NEURAL NETWORKS, BY REGION,
2024?2031 (USD MILLION) 102
TABLE 28 AI IN LIFE SCIENCE MARKET FOR OTHER DEEP LEARNING TOOLS, BY REGION, 2024?2031 (USD MILLION) 103
TABLE 29 AI IN LIFE SCIENCE MARKET FOR SUPERVISED LEARNING, BY REGION,
2024?2031 (USD MILLION) 104
TABLE 30 AI IN LIFE SCIENCE MARKET FOR REINFORCEMENT LEARNING, BY REGION,
2024?2031 (USD MILLION) 105
TABLE 31 AI IN LIFE SCIENCE MARKET FOR UNSUPERVISED LEARNING, BY REGION,
2024?2031 (USD MILLION) 106
TABLE 32 AI IN LIFE SCIENCE MARKET FOR OTHER MACHINE LEARNING TECHNOLOGIES,
BY REGION, 2024?2031 (USD MILLION) 107
TABLE 33 AI IN LIFE SCIENCE MARKET FOR NATURAL LANGUAGE PROCESSING, BY REGION, 2024?2031 (USD MILLION) 108
TABLE 34 AI IN LIFE SCIENCE MARKET FOR CONTEXT-AWARE PROCESSING AND COMPUTING, BY REGION, 2024?2031 (USD MILLION) 109
TABLE 35 AI IN LIFE SCIENCE MARKET FOR COMPUTER VISION, BY REGION,
2024?2031 (USD MILLION) 110
TABLE 36 AI IN LIFE SCIENCE MARKET FOR IMAGE ANALYSIS, BY REGION,
2024?2031 (USD MILLION) 111
TABLE 37 AI IN LIFE SCIENCE MARKET FOR OTHER TOOLS, BY REGION,
2024?2031 (USD MILLION) 112
TABLE 38 AI IN LIFE SCIENCE MARKET, BY APPLICATION, 2024?2031 (USD MILLION) 114
TABLE 39 AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE,
2024?2031 (USD MILLION) 115
TABLE 40 AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY REGION,
2024?2031 (USD MILLION) 115
TABLE 41 AI IN LIFE SCIENCE MARKET FOR DRUG DISCOVERY, BY REGION,
2024?2031 (USD MILLION) 116
TABLE 42 AI IN LIFE SCIENCE MARKET FOR MEDICAL IMAGING AND DIAGNOSTICS,
BY REGION, 2024?2031 (USD MILLION) 117
TABLE 43 AI IN LIFE SCIENCE MARKET FOR CLINICAL TRIALS, BY REGION,
2024?2031 (USD MILLION) 118
TABLE 44 AI IN LIFE SCIENCE MARKET FOR PRECISION MEDICINE, BY REGION,
2024?2031 (USD MILLION) 119
TABLE 45 AI IN LIFE SCIENCE MARKET FOR OTHER CLINICAL APPLICATIONS, BY REGION, 2024?2031 (USD MILLION) 120
TABLE 46 AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY TYPE,
2024?2031 (USD MILLION) 121
TABLE 47 AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY REGION, 2024?2031 (USD MILLION) 121
TABLE 48 AI IN LIFE SCIENCE MARKET FOR R&D SUPPORT, BY REGION,
2024?2031 (USD MILLION) 122
TABLE 49 AI IN LIFE SCIENCE MARKET FOR DATA ANALYTICS AND REPORTING, BY REGION, 2024?2031 (USD MILLION) 123
TABLE 50 AI IN LIFE SCIENCE MARKET FOR MANUFACTURING & QUALITY ASSURANCE,
BY REGION, 2024?2031 (USD MILLION) 124
TABLE 51 AI IN LIFE SCIENCE MARKET FOR REGULATORY AFFAIRS, BY REGION,
2024?2031 (USD MILLION) 125
TABLE 52 AI IN LIFE SCIENCE MARKET, BY COMPONENT, 2024?2031 (USD MILLION) 127
TABLE 53 AI IN LIFE SCIENCE MARKET FOR SOFTWARE, BY REGION,
2024?2031 (USD MILLION) 128
TABLE 54 AI IN LIFE SCIENCE MARKET FOR SERVICE, BY REGION,
2024?2031 (USD MILLION) 129
TABLE 55 AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT, 2024?2031 (USD MILLION) 131
TABLE 56 AI IN LIFE SCIENCE MARKET FOR CLOUD-BASED SOLUTIONS, BY REGION,
2024?2031 (USD MILLION) 132
TABLE 57 AI IN LIFE SCIENCE MARKET FOR ON-PREMISE SOLUTIONS, BY REGION,
2024?2031 (USD MILLION) 133
TABLE 58 AI IN LIFE SCIENCE MARKET FOR HYBRID SOLUTIONS, BY REGION,
2024?2031 (USD MILLION) 134
TABLE 59 AI IN LIFE SCIENCE MARKET, BY END USER, 2024?2031 (USD MILLION) 136
TABLE 60 AI IN LIFE SCIENCE MARKET FOR CRO & CDMO, BY REGION,
2024?2031 (USD MILLION) 137
TABLE 61 AI IN LIFE SCIENCE MARKET FOR PHARMACEUTICAL COMPANIES, BY REGION, 2024?2031 (USD MILLION) 138
TABLE 62 AI IN LIFE SCIENCE MARKET FOR BIOTECHNOLOGY COMPANIES, BY REGION, 2024?2031 (USD MILLION) 139
TABLE 63 AI IN LIFE SCIENCE MARKET FOR DIAGNOSTIC COMPANIES, BY REGION,
2024?2031 (USD MILLION) 140
TABLE 64 AI IN LIFE SCIENCE MARKET FOR ACADEMIC AND GOVERNMENT LABORATORIES, BY REGION, 2024?2031 (USD MILLION) 141
TABLE 65 AI IN LIFE SCIENCE MARKET FOR OTHER END USERS, BY REGION,
2024?2031 (USD MILLION) 142
TABLE 66 AI IN LIFE SCIENCE MARKET, BY OFFERING, 2024?2031 (USD MILLION) 144
TABLE 67 AI IN LIFE SCIENCE MARKET FOR END-TO-END SOLUTIONS, BY REGION,
2024?2031 (USD MILLION) 145
TABLE 68 AI IN LIFE SCIENCE MARKET FOR NICHE/POINT SOLUTIONS, BY REGION,
2024?2031 (USD MILLION) 146
TABLE 69 AI IN LIFE SCIENCE MARKET FOR AI TECHNOLOGY, BY REGION,
2024?2031 (USD MILLION) 147
TABLE 70 AI IN LIFE SCIENCE MARKET FOR SERVICES, BY REGION,
2024?2031 (USD MILLION) 148
TABLE 71 AI IN LIFE SCIENCE MARKET, BY REGION, 2024?2031 (USD MILLION) 150
TABLE 72 NORTH AMERICA: AI IN LIFE SCIENCE MARKET, BY COUNTRY,
2024?2031 (USD MILLION) 152
TABLE 73 NORTH AMERICA: AI IN LIFE SCIENCE MARKET, BY OFFERING,
2024?2031 (USD MILLION) 152
TABLE 74 NORTH AMERICA: AI IN LIFE SCIENCE MARKET, BY APPLICATION,
2024?2031 (USD MILLION) 153
TABLE 75 NORTH AMERICA: AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS,
BY TYPE, 2024?2031 (USD MILLION) 153
TABLE 76 NORTH AMERICA: AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY TYPE, 2024?2031 (USD MILLION) 154
TABLE 77 NORTH AMERICA: AI IN LIFE SCIENCE MARKET, BY COMPONENT,
2024?2031 (USD MILLION) 154
TABLE 78 NORTH AMERICA: AI IN LIFE SCIENCE MARKET, BY TOOL,
2024?2031 (USD MILLION) 155
TABLE 79 NORTH AMERICA: AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE, 2024?2031 (USD MILLION) 155
TABLE 80 NORTH AMERICA: AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE, 2024?2031 (USD MILLION) 156
TABLE 81 NORTH AMERICA: AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT MODE,
2024?2031 (USD MILLION) 156
TABLE 82 NORTH AMERICA: AI IN LIFE SCIENCE MARKET, BY END USER,
2024?2031 (USD MILLION) 157
TABLE 83 US: AI IN LIFE SCIENCE MARKET, BY OFFERING, 2024?2031 (USD MILLION) 158
TABLE 84 US: AI IN LIFE SCIENCE MARKET, BY APPLICATION, 2024?2031 (USD MILLION) 158
TABLE 85 US: AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE,
2024?2031 (USD MILLION) 159
TABLE 86 US: AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY TYPE, 2024?2031 (USD MILLION) 159
TABLE 87 US: AI IN LIFE SCIENCE MARKET, BY COMPONENT, 2024?2031 (USD MILLION) 160
TABLE 88 US: AI IN LIFE SCIENCE MARKET, BY TOOL, 2024?2031 (USD MILLION) 160
TABLE 89 US: AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE,
2024?2031 (USD MILLION) 161
TABLE 90 US: AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE,
2024?2031 (USD MILLION) 161
TABLE 91 US: AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT MODE,
2024?2031 (USD MILLION) 162
TABLE 92 US: AI IN LIFE SCIENCE MARKET, BY END USER, 2024?2031 (USD MILLION) 162
TABLE 93 CANADA: AI IN LIFE SCIENCE MARKET, BY OFFERING, 2024?2031 (USD MILLION) 163
TABLE 94 CANADA: AI IN LIFE SCIENCE MARKET, BY APPLICATION,
2024?2031 (USD MILLION) 164
TABLE 95 CANADA: AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2024?2031 (USD MILLION) 164
TABLE 96 CANADA: AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY TYPE, 2024?2031 (USD MILLION) 165
TABLE 97 CANADA: AI IN LIFE SCIENCE MARKET, BY COMPONENT,
2024?2031 (USD MILLION) 165
TABLE 98 CANADA: AI IN LIFE SCIENCE MARKET, BY TOOL, 2024?2031 (USD MILLION) 166
TABLE 99 CANADA: AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE,
2024?2031 (USD MILLION) 166
TABLE 100 CANADA: AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE,
2024?2031 (USD MILLION) 167
TABLE 101 CANADA: AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT MODE,
2024?2031 (USD MILLION) 167
TABLE 102 CANADA: AI IN LIFE SCIENCE MARKET, BY END USER, 2024?2031 (USD MILLION) 168
TABLE 103 EUROPE: AI IN LIFE SCIENCE MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 169
TABLE 104 EUROPE: AI IN LIFE SCIENCE MARKET, BY OFFERING, 2024?2031 (USD MILLION) 169
TABLE 105 EUROPE: AI IN LIFE SCIENCE MARKET, BY APPLICATION,
2024?2031 (USD MILLION) 170
TABLE 106 EUROPE: AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2024?2031 (USD MILLION) 170
TABLE 107 EUROPE: AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY TYPE, 2024?2031 (USD MILLION) 171
TABLE 108 EUROPE: AI IN LIFE SCIENCE MARKET, BY COMPONENT,
2024?2031 (USD MILLION) 171
TABLE 109 EUROPE: AI IN LIFE SCIENCE MARKET, BY TOOL, 2024?2031 (USD MILLION) 172
TABLE 110 EUROPE: AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE,
2024?2031 (USD MILLION) 172
TABLE 111 EUROPE: AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE,
2024?2031 (USD MILLION) 173
TABLE 112 EUROPE: AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT MODE,
2024?2031 (USD MILLION) 173
TABLE 113 EUROPE: AI IN LIFE SCIENCE MARKET, BY END USER, 2024?2031 (USD MILLION) 174
TABLE 114 GERMANY: AI IN LIFE SCIENCE MARKET, BY OFFERING,
2024?2031 (USD MILLION) 175
TABLE 115 GERMANY: AI IN LIFE SCIENCE MARKET, BY APPLICATION,
2024?2031 (USD MILLION) 175
TABLE 116 GERMANY: AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2024?2031 (USD MILLION) 176
TABLE 117 GERMANY: AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS,
BY TYPE, 2024?2031 (USD MILLION) 176
TABLE 118 GERMANY: AI IN LIFE SCIENCE MARKET, BY COMPONENT,
2024?2031 (USD MILLION) 177
TABLE 119 GERMANY: AI IN LIFE SCIENCE MARKET, BY TOOL, 2024?2031 (USD MILLION) 177
TABLE 120 GERMANY: AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE,
2024?2031 (USD MILLION) 178
TABLE 121 GERMANY: AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE,
2024?2031 (USD MILLION) 178
TABLE 122 GERMANY: AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT MODE,
2024?2031 (USD MILLION) 179
TABLE 123 GERMANY: AI IN LIFE SCIENCE MARKET, BY END USER,
2024?2031 (USD MILLION) 179
TABLE 124 FRANCE: AI IN LIFE SCIENCE MARKET, BY OFFERING, 2024?2031 (USD MILLION) 180
TABLE 125 FRANCE: AI IN LIFE SCIENCE MARKET, BY APPLICATION,
2024?2031 (USD MILLION) 181
TABLE 126 FRANCE: AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2024?2031 (USD MILLION) 181
TABLE 127 FRANCE: AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY TYPE, 2024?2031 (USD MILLION) 182
TABLE 128 FRANCE: AI IN LIFE SCIENCE MARKET, BY COMPONENT,
2024?2031 (USD MILLION) 182
TABLE 129 FRANCE: AI IN LIFE SCIENCE MARKET, BY TOOL, 2024?2031 (USD MILLION) 183
TABLE 130 FRANCE: AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE,
2024?2031 (USD MILLION) 183
TABLE 131 FRANCE: AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE,
2024?2031 (USD MILLION) 184
TABLE 132 FRANCE: AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT MODE,
2024?2031 (USD MILLION) 184
TABLE 133 FRANCE: AI IN LIFE SCIENCE MARKET, BY END USER, 2024?2031 (USD MILLION) 185
TABLE 134 UK: AI IN LIFE SCIENCE MARKET, BY OFFERING, 2024?2031 (USD MILLION) 186
TABLE 135 UK: AI IN LIFE SCIENCE MARKET, BY APPLICATION, 2024?2031 (USD MILLION) 186
TABLE 136 UK: AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE,
2024?2031 (USD MILLION) 187
TABLE 137 UK: AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY TYPE, 2024?2031 (USD MILLION) 187
TABLE 138 UK: AI IN LIFE SCIENCE MARKET, BY COMPONENT, 2024?2031 (USD MILLION) 188
TABLE 139 UK: AI IN LIFE SCIENCE MARKET, BY TOOL, 2024?2031 (USD MILLION) 188
TABLE 140 UK: AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE,
2024?2031 (USD MILLION) 189
TABLE 141 UK: AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE,
2024?2031 (USD MILLION) 189
TABLE 142 UK: AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT MODE,
2024?2031 (USD MILLION) 190
TABLE 143 UK: AI IN LIFE SCIENCE MARKET, BY END USER, 2024?2031 (USD MILLION) 190
TABLE 144 ITALY: AI IN LIFE SCIENCE MARKET, BY OFFERING, 2024?2031 (USD MILLION) 191
TABLE 145 ITALY: AI IN LIFE SCIENCE MARKET, BY APPLICATION, 2024?2031 (USD MILLION) 191
TABLE 146 ITALY: AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE,
2024?2031 (USD MILLION) 192
TABLE 147 ITALY: AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY TYPE, 2024?2031 (USD MILLION) 192
TABLE 148 ITALY: AI IN LIFE SCIENCE MARKET, BY COMPONENT, 2024?2031 (USD MILLION) 193
TABLE 149 ITALY: AI IN LIFE SCIENCE MARKET, BY TOOL, 2024?2031 (USD MILLION) 193
TABLE 150 ITALY: AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE,
2024?2031 (USD MILLION) 194
TABLE 151 ITALY: AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE,
2024?2031 (USD MILLION) 194
TABLE 152 ITALY: AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT MODE,
2024?2031 (USD MILLION) 195
TABLE 153 ITALY: AI IN LIFE SCIENCE MARKET, BY END USER, 2024?2031 (USD MILLION) 195
TABLE 154 SPAIN: AI IN LIFE SCIENCE MARKET, BY OFFERING, 2024?2031 (USD MILLION) 196
TABLE 155 SPAIN: AI IN LIFE SCIENCE MARKET, BY APPLICATION, 2024?2031 (USD MILLION) 196
TABLE 156 SPAIN: AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE,
2024?2031 (USD MILLION) 197
TABLE 157 SPAIN: AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY TYPE, 2024?2031 (USD MILLION) 197
TABLE 158 SPAIN: AI IN LIFE SCIENCE MARKET, BY COMPONENT, 2024?2031 (USD MILLION) 198
TABLE 159 SPAIN: AI IN LIFE SCIENCE MARKET, BY TOOL, 2024?2031 (USD MILLION) 198
TABLE 160 SPAIN: AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE,
2024?2031 (USD MILLION) 199
TABLE 161 SPAIN: AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE,
2024?2031 (USD MILLION) 199
TABLE 162 SPAIN: AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT MODE,
2024?2031 (USD MILLION) 200
TABLE 163 SPAIN: AI IN LIFE SCIENCE MARKET, BY END USER, 2024?2031 (USD MILLION) 200
TABLE 164 REST OF EUROPE: AI IN LIFE SCIENCE MARKET, BY OFFERING,
2024?2031 (USD MILLION) 201
TABLE 165 REST OF EUROPE: AI IN LIFE SCIENCE MARKET, BY APPLICATION,
2024?2031 (USD MILLION) 201
TABLE 166 REST OF EUROPE: AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS,
BY TYPE, 2024?2031 (USD MILLION) 202
TABLE 167 REST OF EUROPE: AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY TYPE, 2024?2031 (USD MILLION) 202
TABLE 168 REST OF EUROPE: AI IN LIFE SCIENCE MARKET, BY COMPONENT,
2024?2031 (USD MILLION) 203
TABLE 169 REST OF EUROPE: AI IN LIFE SCIENCE MARKET, BY TOOL,
2024?2031 (USD MILLION) 203
TABLE 170 REST OF EUROPE: AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE, 2024?2031 (USD MILLION) 204
TABLE 171 REST OF EUROPE: AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE, 2024?2031 (USD MILLION) 204
TABLE 172 REST OF EUROPE: AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT MODE,
2024?2031 (USD MILLION) 205
TABLE 173 REST OF EUROPE: AI IN LIFE SCIENCE MARKET, BY END USER,
2024?2031 (USD MILLION) 205
TABLE 174 ASIA PACIFIC: AI IN LIFE SCIENCE MARKET, BY COUNTRY,
2024?2031 (USD MILLION) 207
TABLE 175 ASIA PACIFIC: AI IN LIFE SCIENCE MARKET, BY OFFERING,
2024?2031 (USD MILLION) 208
TABLE 176 ASIA PACIFIC: AI IN LIFE SCIENCE MARKET, BY APPLICATION,
2024?2031 (USD MILLION) 208
TABLE 177 ASIA PACIFIC: AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2024?2031 (USD MILLION) 208
TABLE 178 ASIA PACIFIC: AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS,
BY TYPE, 2024?2031 (USD MILLION) 209
TABLE 179 ASIA PACIFIC: AI IN LIFE SCIENCE MARKET, BY COMPONENT,
2024?2031 (USD MILLION) 209
TABLE 180 ASIA PACIFIC: AI IN LIFE SCIENCE MARKET, BY TOOL, 2024?2031 (USD MILLION) 210
TABLE 181 ASIA PACIFIC: AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE, 2024?2031 (USD MILLION) 210
TABLE 182 ASIA PACIFIC: AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE,
2024?2031 (USD MILLION) 211
TABLE 183 ASIA PACIFIC: AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT MODE,
2024?2031 (USD MILLION) 211
TABLE 184 ASIA PACIFIC: AI IN LIFE SCIENCE MARKET, BY END USER,
2024?2031 (USD MILLION) 212
TABLE 185 CHINA: AI IN LIFE SCIENCE MARKET, BY OFFERING, 2024?2031 (USD MILLION) 213
TABLE 186 CHINA: AI IN LIFE SCIENCE MARKET, BY APPLICATION, 2024?2031 (USD MILLION) 213
TABLE 187 CHINA: AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE,
2024?2031 (USD MILLION) 213
TABLE 188 CHINA: AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY TYPE, 2024?2031 (USD MILLION) 214
TABLE 189 CHINA: AI IN LIFE SCIENCE MARKET, BY COMPONENT, 2024?2031 (USD MILLION) 214
TABLE 190 CHINA: AI IN LIFE SCIENCE MARKET, BY TOOL, 2024?2031 (USD MILLION) 215
TABLE 191 CHINA: AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE,
2024?2031 (USD MILLION) 215
TABLE 192 CHINA: AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE,
2024?2031 (USD MILLION) 216
TABLE 193 CHINA: AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT MODE,
2024?2031 (USD MILLION) 216
TABLE 194 CHINA: AI IN LIFE SCIENCE MARKET, BY END USER, 2024?2031 (USD MILLION) 217
TABLE 195 JAPAN: AI IN LIFE SCIENCE MARKET, BY OFFERING, 2024?2031 (USD MILLION) 218
TABLE 196 JAPAN: AI IN LIFE SCIENCE MARKET, BY APPLICATION, 2024?2031 (USD MILLION) 218
TABLE 197 JAPAN: AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE,
2024?2031 (USD MILLION) 219
TABLE 198 JAPAN: AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY TYPE, 2024?2031 (USD MILLION) 219
TABLE 199 JAPAN: AI IN LIFE SCIENCE MARKET, BY COMPONENT, 2024?2031 (USD MILLION) 220
TABLE 200 JAPAN: AI IN LIFE SCIENCE MARKET, BY TOOL, 2024?2031 (USD MILLION) 220
TABLE 201 JAPAN: AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE,
2024?2031 (USD MILLION) 221
TABLE 202 JAPAN: AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE,
2024?2031 (USD MILLION) 221
TABLE 203 JAPAN: AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT MODE,
2024?2031 (USD MILLION) 222
TABLE 204 JAPAN: AI IN LIFE SCIENCE MARKET, BY END USER, 2024?2031 (USD MILLION) 222
TABLE 205 INDIA: AI IN LIFE SCIENCE MARKET, BY OFFERING, 2024?2031 (USD MILLION) 223
TABLE 206 INDIA: AI IN LIFE SCIENCE MARKET, BY APPLICATION, 2024?2031 (USD MILLION) 224
TABLE 207 INDIA: AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE,
2024?2031 (USD MILLION) 224
TABLE 208 INDIA: AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY TYPE, 2024?2031 (USD MILLION) 225
TABLE 209 INDIA: AI IN LIFE SCIENCE MARKET, BY COMPONENT, 2024?2031 (USD MILLION) 225
TABLE 210 INDIA: AI IN LIFE SCIENCE MARKET, BY TOOL, 2024?2031 (USD MILLION) 226
TABLE 211 INDIA: AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE,
2024?2031 (USD MILLION) 226
TABLE 212 INDIA: AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE,
2024?2031 (USD MILLION) 227
TABLE 213 INDIA: AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT MODE,
2024?2031 (USD MILLION) 227
TABLE 214 INDIA: AI IN LIFE SCIENCE MARKET, BY END USER, 2024?2031 (USD MILLION) 228TABLE 215 AUSTRALIA: AI IN LIFE SCIENCE MARKET, BY OFFERING,
2024?2031 (USD MILLION) 229
TABLE 216 AUSTRALIA: AI IN LIFE SCIENCE MARKET, BY APPLICATION,
2024?2031 (USD MILLION) 229
TABLE 217 AUSTRALIA: AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2024?2031 (USD MILLION) 230
TABLE 218 AUSTRALIA: AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS,
BY TYPE, 2024?2031 (USD MILLION) 230
TABLE 219 AUSTRALIA: AI IN LIFE SCIENCE MARKET, BY COMPONENT,
2024?2031 (USD MILLION) 231
TABLE 220 AUSTRALIA: AI IN LIFE SCIENCE MARKET, BY TOOL, 2024?2031 (USD MILLION) 231
TABLE 221 AUSTRALIA: AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE, 2024?2031 (USD MILLION) 232
TABLE 222 AUSTRALIA: AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE,
2024?2031 (USD MILLION) 232
TABLE 223 AUSTRALIA: AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT MODE,
2024?2031 (USD MILLION) 233
TABLE 224 AUSTRALIA: AI IN LIFE SCIENCE MARKET, BY END USER,
2024?2031 (USD MILLION) 233
TABLE 225 SOUTH KOREA: AI IN LIFE SCIENCE MARKET, BY OFFERING,
2024?2031 (USD MILLION) 234
TABLE 226 SOUTH KOREA: AI IN LIFE SCIENCE MARKET, BY APPLICATION,
2024?2031 (USD MILLION) 235
TABLE 227 SOUTH KOREA: AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS,
BY TYPE, 2024?2031 (USD MILLION) 235
TABLE 228 SOUTH KOREA: AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS,
BY TYPE, 2024?2031 (USD MILLION) 236
TABLE 229 SOUTH KOREA: AI IN LIFE SCIENCE MARKET, BY COMPONENT,
2024?2031 (USD MILLION) 236
TABLE 230 SOUTH KOREA: AI IN LIFE SCIENCE MARKET, BY TOOL, 2024?2031 (USD MILLION) 237
TABLE 231 SOUTH KOREA: AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE, 2024?2031 (USD MILLION) 237
TABLE 232 SOUTH KOREA: AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE, 2024?2031 (USD MILLION) 238
TABLE 233 SOUTH KOREA: AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT MODE,
2024?2031 (USD MILLION) 238
TABLE 234 SOUTH KOREA: AI IN LIFE SCIENCE MARKET, BY END USER,
2024?2031 (USD MILLION) 239
TABLE 235 REST OF ASIA PACIFIC: AI IN LIFE SCIENCE MARKET, BY OFFERING,
2024?2031 (USD MILLION) 240
TABLE 236 REST OF ASIA PACIFIC: AI IN LIFE SCIENCE MARKET, BY APPLICATION,
2024?2031 (USD MILLION) 240
TABLE 237 REST OF ASIA PACIFIC: AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2024?2031 (USD MILLION) 241
TABLE 238 REST OF ASIA PACIFIC: AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY TYPE, 2024?2031 (USD MILLION) 241
TABLE 239 REST OF ASIA PACIFIC: AI IN LIFE SCIENCE MARKET, BY COMPONENT,
2024?2031 (USD MILLION) 242
TABLE 240 REST OF ASIA PACIFIC: AI IN LIFE SCIENCE MARKET, BY TOOL,
2024?2031 (USD MILLION) 242
TABLE 241 REST OF ASIA PACIFIC: AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING,
BY TYPE, 2024?2031 (USD MILLION) 243
TABLE 242 REST OF ASIA PACIFIC: AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE, 2024?2031 (USD MILLION) 243
TABLE 243 REST OF ASIA PACIFIC: AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT MODE, 2024?2031 (USD MILLION) 244
TABLE 244 REST OF ASIA PACIFIC: AI IN LIFE SCIENCE MARKET, BY END USER,
2024?2031 (USD MILLION) 244
TABLE 245 LATIN AMERICA: AI IN LIFE SCIENCE MARKET, BY COUNTRY,
2024?2031 (USD MILLION) 245
TABLE 246 LATIN AMERICA: AI IN LIFE SCIENCE MARKET, BY OFFERING,
2024?2031 (USD MILLION) 246
TABLE 247 LATIN AMERICA: AI IN LIFE SCIENCE MARKET, BY APPLICATION,
2024?2031 (USD MILLION) 246
TABLE 248 LATIN AMERICA: AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS,
BY TYPE, 2024?2031 (USD MILLION) 246
TABLE 249 LATIN AMERICA: AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY TYPE, 2024?2031 (USD MILLION) 247
TABLE 250 LATIN AMERICA: AI IN LIFE SCIENCE MARKET, BY COMPONENT,
2024?2031 (USD MILLION) 247
TABLE 251 LATIN AMERICA: AI IN LIFE SCIENCE MARKET, BY TOOL,
2024?2031 (USD MILLION) 248
TABLE 252 LATIN AMERICA: AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE, 2024?2031 (USD MILLION) 248
TABLE 253 LATIN AMERICA: AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE, 2024?2031 (USD MILLION) 249
TABLE 254 LATIN AMERICA: AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT MODE,
2024?2031 (USD MILLION) 249
TABLE 255 LATIN AMERICA: AI IN LIFE SCIENCE MARKET, BY END USER,
2024?2031 (USD MILLION) 250
TABLE 256 BRAZIL: AI IN LIFE SCIENCE MARKET, BY OFFERING, 2024?2031 (USD MILLION) 251
TABLE 257 BRAZIL: AI IN LIFE SCIENCE MARKET, BY APPLICATION, 2024?2031 (USD MILLION) 251
TABLE 258 BRAZIL: AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2024?2031 (USD MILLION) 252
TABLE 259 BRAZIL: AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY TYPE, 2024?2031 (USD MILLION) 252
TABLE 260 BRAZIL: AI IN LIFE SCIENCE MARKET, BY COMPONENT, 2024?2031 (USD MILLION) 253
TABLE 261 BRAZIL: AI IN LIFE SCIENCE MARKET, BY TOOL, 2024?2031 (USD MILLION) 253
TABLE 262 BRAZIL: AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE,
2024?2031 (USD MILLION) 254
TABLE 263 BRAZIL: AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE,
2024?2031 (USD MILLION) 254
TABLE 264 BRAZIL: AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT MODE,
2024?2031 (USD MILLION) 255
TABLE 265 BRAZIL: AI IN LIFE SCIENCE MARKET, BY END USER, 2024?2031 (USD MILLION) 255
TABLE 266 MEXICO: AI IN LIFE SCIENCE MARKET, BY OFFERING, 2024?2031 (USD MILLION) 256
TABLE 267 MEXICO: AI IN LIFE SCIENCE MARKET, BY APPLICATION,
2024?2031 (USD MILLION) 257
TABLE 268 MEXICO: AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2024?2031 (USD MILLION) 257
TABLE 269 MEXICO: AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY TYPE, 2024?2031 (USD MILLION) 258
TABLE 270 MEXICO: AI IN LIFE SCIENCE MARKET, BY COMPONENT,
2024?2031 (USD MILLION) 258
TABLE 271 MEXICO: AI IN LIFE SCIENCE MARKET, BY TOOL, 2024?2031 (USD MILLION) 259
TABLE 272 MEXICO: AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE,
2024?2031 (USD MILLION) 259
TABLE 273 MEXICO: AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE,
2024?2031 (USD MILLION) 260
TABLE 274 MEXICO: AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT MODE,
2024?2031 (USD MILLION) 260
TABLE 275 MEXICO: AI IN LIFE SCIENCE MARKET, BY END USER, 2024?2031 (USD MILLION) 261
TABLE 276 REST OF LATIN AMERICA: AI IN LIFE SCIENCE MARKET, BY OFFERING,
2024?2031 (USD MILLION) 262
TABLE 277 REST OF LATIN AMERICA: AI IN LIFE SCIENCE MARKET, BY APPLICATION,
2024?2031 (USD MILLION) 262
TABLE 278 REST OF LATIN AMERICA: AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2024?2031 (USD MILLION) 263
TABLE 279 REST OF LATIN AMERICA: AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY TYPE, 2024?2031 (USD MILLION) 263
TABLE 280 REST OF LATIN AMERICA: AI IN LIFE SCIENCE MARKET, BY COMPONENT,
2024?2031 (USD MILLION) 264
TABLE 281 REST OF LATIN AMERICA: AI IN LIFE SCIENCE MARKET, BY TOOL,
2024?2031 (USD MILLION) 264
TABLE 282 REST OF LATIN AMERICA: AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE, 2024?2031 (USD MILLION) 265
TABLE 283 REST OF LATIN AMERICA: AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING,
BY TYPE, 2024?2031 (USD MILLION) 265
TABLE 284 REST OF LATIN AMERICA: AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT MODE, 2024?2031 (USD MILLION) 266
TABLE 285 REST OF LATIN AMERICA: AI IN LIFE SCIENCE MARKET, BY END USER,
2024?2031 (USD MILLION) 266
TABLE 286 MIDDLE EAST & AFRICA: AI IN LIFE SCIENCE MARKET, BY COUNTRY,
2024?2031 (USD MILLION) 268
TABLE 287 MIDDLE EAST & AFRICA: AI IN LIFE SCIENCE MARKET, BY OFFERING,
2024?2031 (USD MILLION) 268
TABLE 288 MIDDLE EAST & AFRICA: AI IN LIFE SCIENCE MARKET, BY APPLICATION,
2024?2031 (USD MILLION) 269
TABLE 289 MIDDLE EAST & AFRICA: AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2024?2031 (USD MILLION) 269
TABLE 290 MIDDLE EAST & AFRICA: AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY TYPE, 2024?2031 (USD MILLION) 270
TABLE 291 MIDDLE EAST & AFRICA: AI IN LIFE SCIENCE MARKET, BY COMPONENT,
2024?2031 (USD MILLION) 270
TABLE 292 MIDDLE EAST & AFRICA: AI IN LIFE SCIENCE MARKET, BY TOOL,
2024?2031 (USD MILLION) 271
TABLE 293 MIDDLE EAST & AFRICA: AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING,
BY TYPE, 2024?2031 (USD MILLION) 271
TABLE 294 MIDDLE EAST & AFRICA: AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING,
BY TYPE, 2024?2031 (USD MILLION) 272
TABLE 295 MIDDLE EAST & AFRICA: AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT MODE, 2024?2031 (USD MILLION) 272
TABLE 296 MIDDLE EAST & AFRICA: AI IN LIFE SCIENCE MARKET, BY END USER,
2024?2031 (USD MILLION) 273
TABLE 297 GCC: AI IN LIFE SCIENCE MARKET, BY COUNTRY, 2024?2031 (USD MILLION) 273
TABLE 298 GCC: AI IN LIFE SCIENCE MARKET, BY OFFERING, 2024?2031 (USD MILLION) 274
TABLE 299 GCC: AI IN LIFE SCIENCE MARKET, BY APPLICATION, 2024?2031 (USD MILLION) 274
TABLE 300 GCC: AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE,
2024?2031 (USD MILLION) 274
TABLE 301 GCC: AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY TYPE, 2024?2031 (USD MILLION) 275
TABLE 302 GCC: AI IN LIFE SCIENCE MARKET, BY COMPONENT, 2024?2031 (USD MILLION) 275
TABLE 303 GCC: AI IN LIFE SCIENCE MARKET, BY TOOL, 2024?2031 (USD MILLION) 276
TABLE 304 GCC: AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE,
2024?2031 (USD MILLION) 276
TABLE 305 GCC: AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE,
2024?2031 (USD MILLION) 277
TABLE 306 GCC: AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT MODE,
2024?2031 (USD MILLION) 277
TABLE 307 GCC: AI IN LIFE SCIENCE MARKET, BY END USER, 2024?2031 (USD MILLION) 278
TABLE 308 SAUDI ARABIA: AI IN LIFE SCIENCE MARKET, BY OFFERING,
2024?2031 (USD MILLION) 279
TABLE 309 SAUDI ARABIA: AI IN LIFE SCIENCE MARKET, BY APPLICATION,
2024?2031 (USD MILLION) 279
TABLE 310 SAUDI ARABIA: AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2024?2031 (USD MILLION) 280
TABLE 311 SAUDI ARABIA: AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS,
BY TYPE, 2024?2031 (USD MILLION) 280
TABLE 312 SAUDI ARABIA: AI IN LIFE SCIENCE MARKET, BY COMPONENT,
2024?2031 (USD MILLION) 281
TABLE 313 SAUDI ARABIA: AI IN LIFE SCIENCE MARKET, BY TOOL, 2024?2031 (USD MILLION) 281
TABLE 314 SAUDI ARABIA: AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE, 2024?2031 (USD MILLION) 282
TABLE 315 SAUDI ARABIA: AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE,
2024?2031 (USD MILLION) 282
TABLE 316 SAUDI ARABIA: AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT MODE,
2024?2031 (USD MILLION) 283
TABLE 317 SAUDI ARABIA: AI IN LIFE SCIENCE MARKET, BY END USER,
2024?2031 (USD MILLION) 283
TABLE 318 UAE: AI IN LIFE SCIENCE MARKET, BY OFFERING, 2024?2031 (USD MILLION) 285
TABLE 319 UAE: AI IN LIFE SCIENCE MARKET, BY APPLICATION, 2024?2031 (USD MILLION) 285
TABLE 320 UAE: AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE,
2024?2031 (USD MILLION) 285
TABLE 321 UAE: AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY TYPE, 2024?2031 (USD MILLION) 286
TABLE 322 UAE: AI IN LIFE SCIENCE MARKET, BY COMPONENT, 2024?2031 (USD MILLION) 286
TABLE 323 UAE: AI IN LIFE SCIENCE MARKET, BY TOOL, 2024?2031 (USD MILLION) 287
TABLE 324 UAE: AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE,
2024?2031 (USD MILLION) 287
TABLE 325 UAE: AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE,
2024?2031 (USD MILLION) 288
TABLE 326 UAE: AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT MODE,
2024?2031 (USD MILLION) 288
TABLE 327 UAE: AI IN LIFE SCIENCE MARKET, BY END USER, 2024?2031 (USD MILLION) 289
TABLE 328 REST OF GCC: AI IN LIFE SCIENCE MARKET, BY OFFERING,
2024?2031 (USD MILLION) 290
TABLE 329 REST OF GCC: AI IN LIFE SCIENCE MARKET, BY APPLICATION,
2024?2031 (USD MILLION) 290
TABLE 330 REST OF GCC: AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2024?2031 (USD MILLION) 290
TABLE 331 REST OF GCC: AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS,
BY TYPE, 2024?2031 (USD MILLION) 291
TABLE 332 REST OF GCC: AI IN LIFE SCIENCE MARKET, BY COMPONENT,
2024?2031 (USD MILLION) 291
TABLE 333 REST OF GCC: AI IN LIFE SCIENCE MARKET, BY TOOL, 2024?2031 (USD MILLION) 292
TABLE 334 REST OF GCC: AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE, 2024?2031 (USD MILLION) 292
TABLE 335 REST OF GCC: AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE,
2024?2031 (USD MILLION) 293
TABLE 336 REST OF GCC: AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT MODE,
2024?2031 (USD MILLION) 293
TABLE 337 REST OF GCC: AI IN LIFE SCIENCE MARKET, BY END USER,
2024?2031 (USD MILLION) 294
TABLE 338 SOUTH AFRICA: AI IN LIFE SCIENCE MARKET, BY OFFERING,
2024?2031 (USD MILLION) 295
TABLE 339 SOUTH AFRICA: AI IN LIFE SCIENCE MARKET, BY APPL